NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors
Retrieved on:
Monday, January 9, 2023
Responsive neurostimulation device, Wall Street, EEG, Ramot at Tel Aviv University, Startup company, Conference, Growth, Patient, University Center, Epilepsy, Liver, Tel Aviv University, Book, Joel S. Migdal, Law, Anticonvulsant, Business, Video game, Lithium, Health insurance, Animal, Management, Meridian
Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021.
Key Points:
- Total revenue is expected to be approximately $12.8 million, representing growth of 16% compared to $11.0 million in the fourth quarter of 2021.
- Initial implant revenue is expected to be approximately $9.8 million, representing growth of 15% compared to $8.5 million in the fourth quarter of 2021.
- Replacement implant revenue is expected to be approximately $1.4 million, representing a decline of 44% compared to $2.5 million in the fourth quarter of 2021.
- Additionally, NeuroPace announced the appointment of Dr. Uri Geiger to its Board of Directors, effective January 5, 2023.